Depomed has announced that Lazanda (fentanyl) nasal spray, CII, is now available at 300 mcg dose strength to treat breakthrough cancer pain. Lazanda had previously been available in 100 and 400 mcg doses of fentanyl base, with each spray containing 100 mcL of solution.
The introduction of the 300 mcg dose will help physicians in titrating and matching optimal doses to match individual patient needs. If adequate pain relief is not achieved with the starting dose of 100 mcg, Lazanda can now be titrated to 200, 300, 400, 600, or 800 mcg.
Lazanda is the only FDA-approved, nasally-delivered, transmucosal immediate release fentanyl (TIRF) for adults with breakthrough cancer pain. It is indicated to treat patients 18 years of age and older who are already receiving opioid therapy for underlying persistent cancer pain.
The spray provides an alternate for patients with breakthrough cancer pain who struggle to swallow due to nausea, or who experience vomiting, mucositis, ulcers and dry mouth.
Lazanda is only available to patients enrolled in the TIRF REMS Access program.
For more information visit Lazanda.com.
This article originally appeared on MPR